Recent 8-K filings for AORT

• May 18, 2026, 7:06 AM ET M&A materiality 0.75 positive item 7.01item 8.01item 9.01

  Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft

  Net purchase price of $135M funded via $150M delayed draw term loan.

• May 15, 2026, 3:13 PM ET other materiality 0.15 neutral item 5.07item 9.01

  Artivion stockholders elect all nine director nominees and approve say-on-pay at 2026 annual meeting

  All nine nominees elected; highest vote count for Anthony B. Semedo (39,241,704 for) and lowest for Jeffrey H. Burbank (34,250,202 for).

• May 7, 2026, 7:59 PM ET M&A materiality 0.85 negative item 1.01item 2.02item 9.01 ◈ Earnings Releases◈ Material Agreements

  Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net

  Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.

• February 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M

  GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.

• November 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance

  Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.

• September 29, 2025, 7:59 PM ET other material materiality 0.30 neutral item 1.01item 9.01

  Artivion (AORT) to acquire two Austin office/manufacturing buildings for $20.5M cash

  Purchase price $12.05M for existing On-X manufacturing buildings (75k sq ft) and $8.45M for adjacent 87k sq ft expansion.

• September 15, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings ×2

  Artivion extends credit facility maturities to 2031, adds $150M delayed draw term loan

  Maturity of existing term loans and revolving credit facility extended to January 18, 2031.

• August 11, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02item 9.01

  Artivion appoints Lance Berry as COO, retains CFO role; CMO Stanton to retire March 2026

  Lance Berry appointed COO effective Aug 11, 2025, while continuing as CFO and Treasurer.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance

  Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.

• May 29, 2025, 7:59 PM ET debt materiality 0.75 positive item 3.02item 8.01item 9.01

  Artivion exchanges $99.5M of convertible notes for 4.3M shares; nearly eliminates 2025 debt

  Exchanged $99.54M principal of 4.250% convertibles due 2025 for 4,334,347 shares of common stock.

• May 16, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Artivion shareholders approve 3.57M share increase for equity incentive plan

  All nine director nominees elected; say-on-pay and auditor ratification approved.

• May 14, 2025, 7:59 PM ET other material materiality 0.75 positive item 3.02item 8.01item 9.01

  Artivion agrees to exchange ~$95M of 2025 convertible notes for common stock

  Enters private exchange agreements with holders of 4.250% convertible notes due July 2025; ~$94.54M principal to be exchanged for shares.

• May 5, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance

  Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.

• February 24, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M

  Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.

• December 23, 2024, 6:59 PM ET other material materiality 0.55 neutral item 8.01item 9.01

  Artivion changes conversion settlement method on its 4.25% Convertible Notes due 2025 to Physical Settlement

  On Dec 23, 2024, Artivion notified holders it is changing the default settlement method for its convertible notes to Physical Settlement.

• December 9, 2024, 6:59 PM ET cyber materiality 0.65 negative item 8.01item 9.01

  Artivion reports cybersecurity incident discovered Nov 21; systems taken offline

  Incident involved acquisition and encryption of files; external advisors engaged.

• December 9, 2024, 6:59 PM ET regulatory materiality 0.50 positive item 8.01item 9.01

  FDA grants Artivion HDE for AMDS Hybrid Prosthesis in acute DeBakey Type I dissections with malperfusion

  HDE covers ~40% of US acute DeBakey Type I dissections; PMA expected late 2025 for full $150M annual market.

• November 7, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M

  Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Artivion Q2 revenue $98M (+10% YoY), narrows net loss, raises FY24 guidance

  Revenue $98.0M (+10% GAAP and constant currency); net loss ($2.1M) vs ($3.4M) YoY.

• July 1, 2024, 7:59 PM ET M&A materiality 0.65 neutral item 1.01item 7.01item 9.01

  Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net

  Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.

• May 17, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.03item 9.01 ◈ Governance Changes

  Artivion amends bylaws, narrows stockholder advance notice requirements

  Board approved amended bylaws effective May 15, 2024; updates advance notice rules for stockholder nominations and proposals.

• May 16, 2024, 7:59 PM ET other materiality 0.30 neutral item 5.03item 5.07item 9.01 ◈ Shareholder Votes ×4◈ Governance Changes

  Artivion stockholders approve officer exculpation charter amendment at 2024 annual meeting

  Stockholders approved amendment to certificate of incorporation allowing officer exculpation under Delaware law; effective May 15, 2024.

• May 6, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Artivion Q1 revenue $97.4M (+17% YoY); nets $7.5M income vs loss; raises FY24 guidance

  Revenue $97.4M, up 17% GAAP (16% constant currency) vs $83.2M in Q1 2023.

• February 15, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases ×3

  Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M

  Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).

• January 18, 2024, 6:59 PM ET debt materiality 0.80 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings◈ Material Agreements

  Artivion enters $350M credit facility with Ares Capital, refinances existing debt

  Entered $350M credit facility: $190M initial term loan, $100M delayed draw term loan, $60M revolving credit facility.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

12 positive 2 negative 11 neutral

source · AORT on sec.gov